

0400

OIPE

ENTERED

RAW SEQUENCE LISTING DATE: 11/29/2000
PATENT APPLICATION: US/09/711,022 TIME: 09:12:34

Input Set : A:\V1397028.txt
Output Set: N:\CRF3\11292000\T711022.raw

RAW SEQUENCE LISTING DATE: 11/29/2000
 PATENT APPLICATION: US/09/711,022 TIME: 09:12:34

Input Set : A:\V1397028.txt
 Output Set: N:\CRF3\11292000\I711022.raw

```

61 <213> ORGANISM: Homo Sapiens
63 <400> SEQUENCE: 2
64 Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr
65   1           5          10          15
66 Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys
67   20          25          30
68 Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu
69   35          40          45
70 Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gin Thr Arg Ile
71   50          55          60
72 Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp
73   65          70          75          80
74 Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr
75   85          90          95
76 Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly
77   100         105         110
78 Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg
79   115         120         125
80 Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr
81   130         135         140
82 Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile
83   145         150         155         160
84 Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu
85   165         170         175
86 Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp
87   180         185         190
88 Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met
89   195         200         205
90 Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg
91   210         215         220
92 Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro
93   225         230         235         240
94 Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly
95   245         250         255
96 Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg
97   260         265         270
98 Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
99   275         280         285

101 <210> SEQ ID NO: 3
102 <211> LENGTH: 1424
103 <212> TYPE: DNA
104 <213> ORGANISM: Homo Sapiens
106 <400> SEQUENCE: 3
107 aggagcccta ggaggtaacgg ggagctcgca aatactccctt ttgggtttattt cttaccacct      60
108 tyccttcgtg ttccctggga atgcgtgtgt gcttatgtat ctgggtctctt tttggagacta      120
109 cagtggacag gcatttgtga cagcaactatq ggactqagta acattctctt tgtgtatggcc      180
110 ttccctgtctt ctgggtctgc tcctctgaag attcaagctt atttcaatga qactgcagac      240
111 ctqccatgcc aatttgcaaa ctctcaaaaac caaaggcctga gtgagctagt agtattttgg      300
112 cayggaccagg aaaacttgtt tctyaatgag gtatacttag gcaaaagagaa atttgacagt      360

```

RAW SEQUENCE LISTING DATE: 11/29/2000
PATENT APPLICATION: US/09/711,022 TIME: 09:12:34

Input Set : A:\V1397028.txt
Output Set: N:\CREF\11292000\I711022.raw

```

113 gttcattcca agtatataatggg ccgcacaagt ttgttattcgq acagttggac cctgaaactt
114 cacaatcttc agatcaaggaa caagggttgc tatcaatgtt tcatccatca caaaaagccc 480
115 acaggaaatgtt ttgcgtatccca ccagatgaat tctgaaatgtt cagtgtttcc taaccttcaat 540
116 caacctgtttaa tagtaccat ttctataatataa acagaaaaatgtt tgatcataaaat ttgcaccttc 600
117 tcatctatac aacgttaccc agaaacttaaag aagatgttttttccatcaaaatgtt 660
118 tcaactatcg agtatgtatgg tattatgcgg aataatctcaatc agatgttccaaatgtt 720
119 qacgttccca tcagttgttc tggtttccatcc cctgtatgttca cgaccaatataat gaccatcttc 780
120 tggatcttgg aaactgacaa gacgcggctt ttatcttccat ctttcttctat agagtttgag 840
121 gacccttcacg ctccccccaga ccacatccatc tggattacag ctgttttccat aacagtattt 900
122 atatgttgc tggtttttctg tctaatttcaatc tggaaatgttca agaauagaaa ycggttccgc 960
123 aactcttataa aatgtggacaa caacacatgttca gagagggaaatgttca gaccaagaaa 1020
124 agagaaaaaa tccatataacc tggaaatgttcaatc gatgttccatcc acgtgtttttt taaaatgttcc 1080
125 aagacatctt catgcgacaa aagtgtataca tggatctttaat taaaagatgttca agccatata 1140
126 agtatttattt tttcttccatc tttcttcttgc tggatcttgc gcaacccctt tggatcttcc 1200
127 caaaatgttca aaaaatgttcaatc ccacatgttca tggatcttgc gcaacccctt tggatcttcc 1260
128 aataatgttccatcc ctgttacttcc agctctgttc cgtatgttccaa gaccaatataat taaaatgttcc 1320
129 actgttttttccatccatc tggatcttgc gacacatcttcaatc tggatcttgc gcaacccctt tggatcttcc 1380
130 ctggaaataaa aattttaggac caataaaaaaa aaaaaaaaaaaa aaaaa 1424

132 <210> SEQ ID NO: 4
133 <211> LENGTH: 323
134 <212> TYPE: PRT
135 <213> ORGANISM: Homo Sapiens
137 <400> SEQUENCE: 4
138 Met Gly Leu Ser Asn Ile Leu Phe Val Met Ala Phe Leu Leu Ser Gly
139      1           5           10          15
140 Ala Ala Pro Leu Lys Ile Glu Ala Tyr Phe Asn Glu Thr Ala Asp Leu
141             20          25          30
142 Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln Ser Leu Ser Glu Leu Val
143       35          40          45
144 Val Phe Trp Gln Asp Gln Glu Asn Leu Val Leu Asn Glu Val Tyr Leu
145       50          55          60
146 Gly Lys Glu Lys Phe Asp Ser Val His Ser Lys Tyr Met Gly Arg Thr
147       65          70          75          80
148 Ser Phe Asp Ser Asp Ser Trp Thr Leu Arg Leu His Asn Leu Gln Ile
149             85          90          95
150 Lys Asp Lys Gly Leu Tyr Gln Cys Ile Ile His His Lys Lys Pro Thr
151             100         105         110
152 Gly Met Ile Arg Ile His Gln Met Asn Ser Glu Leu Ser Val Leu Ala
153             115         120         125
154 Asn Phe Ser Gln Pro Glu Ile Val Pro Ile Ser Asn Ile Thr Glu Asn
155             130         135         140
156 Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile His Gly Tyr Pro Glu Pro
157             145         150         155          160
158 Lys Lys Met Ser Val Leu Leu Arg Thr Lys Asn Ser Thr Ile Gln Tyr
159             165         170         175
160 Asp Gly Ile Met Gln Lys Ser Gln Asp Asn Val Thr Glu Leu Tyr Asp
161             180         185         190
162 Val Ser Ile Ser Leu Ser Val Ser Phe Pro Asp Val Thr Ser Asn Met
163             195         200         205

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/711,022

DATE: 11/29/2000
TIME: 09:12:34

Input Set : A:\V1397028.txt
Output Set: N:\CRF3\11292000\I711022.raw

```

164 Thr Ile Phe Cys Ile Leu Glu Thr Asp Lys Thr Arg Leu Leu Ser Ser
165      210          215          220
166 Pro Phe Ser Ile Glu Leu Glu Asp Pro Gln Pro Pro Pro Asp His Ile
167      225          230          235          240
168 Pro Trp Ile Thr Ala Val Leu Pro Thr Val Ile Ile Cys Val Met Val
169      245          250          255
170 Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys Lys Arg Pro Arg Asn
171      260          265          270
172 Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu Arg Glu Glu Ser Glu Glu
173      275          280          285
174 Thr Lys Lys Arg Glu Lys Ile His Ile Pro Glu Arg Ser Asp Glu Ala
175      290          295          300
176 Gln Arg Val Phe Lys Ser Ser Lys Thr Ser Ser Cys Asp Lys Ser Asp
177      305          310          315          320
178 Thr Cys Phe
181 <210> SEQ ID NO: 5
182 <211> LENGTH: 924
183 <212> TYPE: DNA
184 <213> ORGANISM: Homo Sapiens
186 <400> SEQUENCE: 5
187 atqgggggccc tgcacgcctc ggacgtacac cccgaccctgg ggggtccagct ctttcgtcgat    60
188 ggaatagcgg cgtgttggc ggacgtgate accttccccgc tggcacacggc caaagtccgg 120
189 ctccaggtcc aagggtqaatg cccgacgtcc agtgttatta ggtataaaagg tggctctggga 180
190 acaatcaccg ctgtgttaaa aacagaaggg cggatgaaaac ttcacagcggg gctgcctqcg 240
191 gggcttcagc ggcaatcagc ctcgcctct ctcaggatcg gctctacqg cacggtccag 300
192 gagttcttca cccgaggaa agaaaacagca cctatgttag gaagcaagat tttagcttgt 360
193 ctaacqactg gaggagtggc agtatttcatt gggcaacccca cagaggtcggt gaaagtcaaga 420
194 cttcaaycac agagccatct ccacggaaatc aaacccctcgat acacggggac ttataatgcg 480
195 tacaqaataa tagcaacaac cgaaggcttg acgggtttt ggaaaggggac tactcccaat 540
196 ctgtatgaaat gtgtcatcat caattgtaca gagctatcaa catatgtatc aatgaaggag 600
197 gcctttgtaa aaaaacacat attagcatg gacgtccccct gccacttgt gtrqgcttt 660
198 atcgtctggat tttgcgcaac agctatqtcc tccccqgtgg atgtatgaa aaccagattt 720
199 attaatttctc caccaggaca gtacaaaagt gtgccaact gtgcaatgaa agtgttcaact 780
200 aacgaaaggac caacggcttt ctccaagggg ttgttacctt ctttcttgcc acitggatcc 840
201 tggaaacgtca ttatgttgt gtgttttggaa caactgaaac gagaactgtc aaagtcaagg 900
202 cagactatgg actgtgccac ataa                                         924
204 <210> SEQ ID NO: 6
205 <211> LENGTH: 307
206 <212> TYPE: PRT
207 <213> ORGANISM: Homo Sapiens
209 <400> SEQUENCE: 6
210 Met Gly Gly Leu Thr Ala Ser Asp Val His Pro Thr Leu Gly Val Gln
211 1           5           10          15
212 Leu Phe Ser Ala Gly Ile Ala Ala Cys Leu Ala Asp Val Ile Thr Phe
213 20          25          30
214 Pro Leu Asp Thr Ala Lys Val Arg Leu Gln Val Gln Gly Glu Cys Pro
215 35          40          45
216 Thr Ser Ser Val Ile Arg Tyr Lys Gly Val Leu Gly Thr Ile Thr Ala
217 50          55          60

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/711,022

DATE: 11/29/2000
TIME: 09:12:34

Input Set : A:\V1397028.txt
Output Set: N:\CRF3\11292000\I711022.raw

```

218 Val Val Lys Thr Glu Gly Arg Met Lys Leu Tyr Ser Gly Leu Pro Ala
219   65           70           75           80
220 Gly Leu Gln Arg Gln Ile Ser Ser Ala Ser Leu Arg Ile Gly Leu Tyr
221           85           90           95
222 Asp Thr Val Gln Glu Phe Leu Thr Ala Gly Lys Glu Thr Ala Pro Ser
223           100          105          110
224 Leu Gly Ser Lys Ile Leu Ala Gly Leu Thr Thr Gly Gly Val Ala Val
225           115          120          125
226 Phe Ile Gly Gln Pro Thr Glu Val Val Lys Val Arg Leu Gln Ala Gln
227           130          135          140
228 Ser His Leu His Gly Ile Lys Pro Arg Tyr Thr Gly Thr Tyr Asn Ala
229           145          150          155          160
230 Tyr Arg Ile Ile Ala Thr Thr Glu Gly Leu Thr Gly Leu Trp Lys Gly
231           165          170          175
232 Thr Thr Pro Asn Leu Met Arg Ser Val Ile Ile Asn Cys Thr Glu Leu
233           180          185          190
234 Val Thr Tyr Asp Leu Met Lys Glu Ala Phe Val Lys Asn Asn Ile Leu
235           195          200          205
236 Ala Asp Asp Val Pro Cys His Leu Val Ser Ala Leu Ile Ala Gly Phe
237           210          215          220
238 Cys Ala Thr Ala Met Ser Ser Pro Val Asp Val Val Lys Thr Arg Phe
239           225          230          235          240
240 Ile Asn Ser Pro Pro Gly Gln Tyr Lys Ser Val Pro Asn Cys Ala Met
241           245          250          255
242 Lys Val Phe Thr Asn Glu Gly Pro Thr Ala Phe Phe Lys Gly Leu Val
243           260          265          270
244 Pro Ser Phe Leu Arg Leu Gly Ser Trp Asn Val Ile Met Phe Val Cys
245           275          280          285
246 Phe Glu Gln Leu Lys Arg Glu Leu Ser Lys Ser Arg Gln Thr Met Asp
247           290          295          300
248 Cys Ala Thr
249   305
251 <210> SEQ ID NO: 7
252 <211> LENGTH: 1105
253 <212> TYPE: DNA
254 <213> ORGANISM: Homo Sapiens
255 <400> SEQUENCE: 7
256
257 gttcccttat ctgcgtttgt tgctgattaa aggtggccct gtctccagg tttctccatc      60
258 tcctgggacg tgcaggaaa tcagcatcat gggtgggttc aaggccacag atgtgcccc 120
259 tactgcact gtgaagtttc ttggggctgg cacagctgcc tgcategcag atctcatcac 180
260 ctttccctq gatactgcta aagtccggtt acagatccaa ggagaaaatgc agggggcagt 240
261 gcgcgcatac gccagcgccc aqtaaccgcgg tqtgatggc accatttcgtca ccatggtgcg 300
262 tactgagggc ccccgaaagcc tctacaatgg gctgqttgcc ggcctgcagc gccaaatgag 360
263 ctttgcctct gtccgcateg gcctgtatga tttctgtcaaa cagttctaca ccaagggttc 420
264 tgagcatgcc aycatggga gccgcctctt aqcaaggcagc accacacggtg ccctggctgt 480
265 ggctgtggcc cagccccacgg atgttgtaaa ggtccgatcc caagctcagg cccggggctgg 540
266 aggttgttcgg agataccaaa qcaccgtcaa tgcttacaag accattgccc gagaggaagg 600
267 gttccggggc ctctgaaaaa ggaccttc caatgttgct cgtaatgcctt ttgtcaactg 660
268 tgcgtgatcg glgacatcg acctcatcaa ygatggccctc ctgaaagccaa acctcatgac 720

```

VERIFICATION SUMMARY DATE: 11/29/2000
PATENT APPLICATION: US/09/711,022 TIME: 09:12:35

Input Set : A:\V1397028.txt
Output Set: N:\CRF3\11292000\I711022.raw

L:13 M:270 C: Current Application Number differs, Replaced Current Application No
L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date

Thurs 8pm

Jen^{sh} i F_{er}n

- ~~23. The method of claim 18, wherein the MHC class II HLA-DR inducing agent is adriamycin.~~

24. The method of claim 18, wherein the MHC class II HLA-DR inducing agent
5 is gamma interferon.

25. The method of claim 18, wherein the MHC class II HLA-DR inducing agent is selected from the group consisting of a UCR expression vector, a TCR $\alpha\beta$ engagement molecule and a fatty acid.

10

26. The method of claim 18, wherein the endogenous MHC class II HLA-DR ligand is an MHC class II HLA-DR expressing cell.

25 32 35-36 0

27. The method of claim 18, wherein the MHC class II HLA-DR inducing agent is administered orally.

28. The method of claim 18, wherein the MHC class II HLA-DR inducing agent is administered locally.

20

29. A method for inducing apoptosis in a tumor cell, comprising:

De F
pg 26

contacting a tumor cell with an amount of a metabolic modifying agent, which when exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to increase the mitochondrial membrane potential in the tumor cell, and

Korsenyer

Page 24

66

25

- contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent effective for inducing apoptosis in the tumor cell.

\Rightarrow C_6 et c_{ph} Dxp \Rightarrow Fus \Rightarrow c_{ph}

adm pg 10

pg 7 tumor cells
not adrenocortical

30. The method of claim 29, wherein the metabolic modifying agent is glucose.

30

31. The method of claim 29, wherein the metabolic modifying agent is an MHC class II HLA-DP/DQ ligand.

32. The method of claim 29, wherein the metabolic modifying agent is selected from the group consisting of phorbol myristate acetate in combination with ionomycin, GDP, CD40 binding peptide, sodium acetate, UCP antisense, dominant negative UCP, and staurosporine.

Pg 12 New Fox ligand leading to increased melanoma, colon carcinoma

5

*Fig 23 & 24
New Peptides*

33. The method of claim 29, wherein the metabolic modifying agent is GDP.

cell

34. The method of claim 29, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of ~~adriamycin~~, cytarabine, doxorubicin, and methotrexate.

*Pg 10 HL60MDR B7 induced cell Pg 17
human pro myelocytic cell line*

10

35. The method of claim 29, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously.

15

36. The method of claim 29, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally.

37. The method of claim 35, wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.

20.

38. The method of claim 29, wherein the tumor cell is sensitive to the apoptotic chemotherapeutic agent, and wherein the amount of metabolic modifying agent is effective to increase mitochondrial membrane potential and the amount of apoptotic chemotherapeutic agent is effective to inhibit the proliferation of the tumor cell when the mitochondrial membrane potential is increased.

In Mit membrane potential

proto-oncogene

~~39. A method for decreasing mitochondrial membrane potential in a cell of a subject, comprising~~

30

administering an MHC class II HLA-DR ligand to the subject to selectively engage MHC class II HLA-DR on the surface of the cell in an amount effective to decrease mitochondrial membrane potential in the mammalian cell.